atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
kalmente (nionase) nefúði, dreifa 50 míkróg/skammt
zentiva k.s.* - mometasonum fúróat - nefúði, dreifa - 50 míkróg/skammt
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lyf til veikindi öndunarvegi sjúkdómum, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
mometason apofri nefúði, dreifa 50 míkróg/skammt
evolan pharma ab - mometasonum fúróat - nefúði, dreifa - 50 míkróg/skammt
nasonex nefúði, dreifa 50 míkróg/skammt
n.v. organon* - mometasonum fúróat - nefúði, dreifa - 50 míkróg/skammt
elocon krem 0,1 %
n.v. organon* - mometasonum fúróat - krem - 0,1 %
elocon smyrsli 0,1 %
n.v. organon* - mometasonum fúróat - smyrsli - 0,1 %
elocon húðlausn 0,1 %
n.v. organon* - mometasonum fúróat - húðlausn - 0,1 %